AdvanCell Isotopes is a startup based in Australia, most recent round Series-c-plus, 3 tracked investors.
AdvanCell Isotopes is a startup founded in 2020 based in Australia. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
AdvanCell Isotopes is an Australian company developing 212Pb-based targeted alpha radiotherapeutics and operates a 212Pb isotope manufacturing capability; it is advancing a 212Pb PSMA-targeting radioligand for prostate cancer alongside a pipeline of radiotherapeutic programs.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.